Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects

Andreas R Baudy, Erica K M Reeves, Jesse M Damsker, Christopher Heier, Lindsay M Garvin, Blythe C Dillingham, John McCall, Sree Rayavarapu, Zuyi Wang, Jack H Vandermeulen, Arpana Sali, Vanessa Jahnke, Stephanie Duguez, Debra DuBois, Mary C Rose, Kanneboyina Nagaraju, Eric P Hoffman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Glucocorticoids are standard of care for many inflammatory conditions, but chronic use is associated with a broad array of side effects. This has led to a search for dissociative glucocorticoids--drugs able to retain or improve efficacy associated with transrepression [nuclear factor-κB (NF-κB) inhibition] but with the loss of side effects associated with transactivation (receptor-mediated transcriptional activation through glucocorticoid response element gene promoter elements). We investigated a glucocorticoid derivative with a Δ-9,11 modification as a dissociative steroid. The Δ-9,11 analog showed potent inhibition of tumor necrosis factor-α-induced NF-κB signaling in cell reporter assays, and this transrepression activity was blocked by 17β-hydroxy-11β-[4-dimethylamino phenyl]-17α-[1-propynyl]estra-4,9-dien-3-one (RU-486), showing the requirement for the glucocorticoid receptor (GR). The Δ-9,11 analog induced the nuclear translocation of GR but showed the loss of transactivation as assayed by GR-luciferase constructs as well as mRNA profiles of treated cells. The Δ-9,11 analog was tested for efficacy and side effects in two mouse models of muscular dystrophy: mdx (dystrophin deficiency), and SJL (dysferlin deficiency). Daily oral delivery of the Δ-9,11 analog showed a reduction of muscle inflammation and improvements in multiple muscle function assays yet no reductions in body weight or spleen size, suggesting the loss of key side effects. Our data demonstrate that a Δ-9,11 analog dissociates the GR-mediated transcriptional activities from anti-inflammatory activities. Accordingly, Δ-9,11 analogs may hold promise as a source of safer therapeutic agents for chronic inflammatory disorders.
LanguageEnglish
Pages225-232
JournalThe Journal of Pharmacology and Experimental Therapeutics
Volume343
Issue number1
DOIs
Publication statusPublished - 10 Oct 2012

Fingerprint

Glucocorticoid Receptors
Response Elements
Glucocorticoids
Transcriptional Activation
Mifepristone
Muscles
Dystrophin
Muscular Dystrophies
Standard of Care
Luciferases
Anti-Inflammatory Agents
Spleen
Tumor Necrosis Factor-alpha
Steroids
Body Weight
Inflammation
Messenger RNA
Pharmaceutical Preparations
Genes
Therapeutics

Keywords

  • glucocorticoids

Cite this

Baudy, Andreas R ; Reeves, Erica K M ; Damsker, Jesse M ; Heier, Christopher ; Garvin, Lindsay M ; Dillingham, Blythe C ; McCall, John ; Rayavarapu, Sree ; Wang, Zuyi ; Vandermeulen, Jack H ; Sali, Arpana ; Jahnke, Vanessa ; Duguez, Stephanie ; DuBois, Debra ; Rose, Mary C ; Nagaraju, Kanneboyina ; Hoffman, Eric P. / Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects. In: The Journal of Pharmacology and Experimental Therapeutics. 2012 ; Vol. 343, No. 1. pp. 225-232.
@article{4cb57f2890b74799a2289f93006a3351,
title = "Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects",
abstract = "Glucocorticoids are standard of care for many inflammatory conditions, but chronic use is associated with a broad array of side effects. This has led to a search for dissociative glucocorticoids--drugs able to retain or improve efficacy associated with transrepression [nuclear factor-κB (NF-κB) inhibition] but with the loss of side effects associated with transactivation (receptor-mediated transcriptional activation through glucocorticoid response element gene promoter elements). We investigated a glucocorticoid derivative with a Δ-9,11 modification as a dissociative steroid. The Δ-9,11 analog showed potent inhibition of tumor necrosis factor-α-induced NF-κB signaling in cell reporter assays, and this transrepression activity was blocked by 17β-hydroxy-11β-[4-dimethylamino phenyl]-17α-[1-propynyl]estra-4,9-dien-3-one (RU-486), showing the requirement for the glucocorticoid receptor (GR). The Δ-9,11 analog induced the nuclear translocation of GR but showed the loss of transactivation as assayed by GR-luciferase constructs as well as mRNA profiles of treated cells. The Δ-9,11 analog was tested for efficacy and side effects in two mouse models of muscular dystrophy: mdx (dystrophin deficiency), and SJL (dysferlin deficiency). Daily oral delivery of the Δ-9,11 analog showed a reduction of muscle inflammation and improvements in multiple muscle function assays yet no reductions in body weight or spleen size, suggesting the loss of key side effects. Our data demonstrate that a Δ-9,11 analog dissociates the GR-mediated transcriptional activities from anti-inflammatory activities. Accordingly, Δ-9,11 analogs may hold promise as a source of safer therapeutic agents for chronic inflammatory disorders.",
keywords = "glucocorticoids",
author = "Baudy, {Andreas R} and Reeves, {Erica K M} and Damsker, {Jesse M} and Christopher Heier and Garvin, {Lindsay M} and Dillingham, {Blythe C} and John McCall and Sree Rayavarapu and Zuyi Wang and Vandermeulen, {Jack H} and Arpana Sali and Vanessa Jahnke and Stephanie Duguez and Debra DuBois and Rose, {Mary C} and Kanneboyina Nagaraju and Hoffman, {Eric P}",
year = "2012",
month = "10",
day = "10",
doi = "10.1124/jpet.112.194340",
language = "English",
volume = "343",
pages = "225--232",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
number = "1",

}

Baudy, AR, Reeves, EKM, Damsker, JM, Heier, C, Garvin, LM, Dillingham, BC, McCall, J, Rayavarapu, S, Wang, Z, Vandermeulen, JH, Sali, A, Jahnke, V, Duguez, S, DuBois, D, Rose, MC, Nagaraju, K & Hoffman, EP 2012, 'Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects', The Journal of Pharmacology and Experimental Therapeutics, vol. 343, no. 1, pp. 225-232. https://doi.org/10.1124/jpet.112.194340

Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects. / Baudy, Andreas R; Reeves, Erica K M; Damsker, Jesse M; Heier, Christopher; Garvin, Lindsay M; Dillingham, Blythe C; McCall, John; Rayavarapu, Sree; Wang, Zuyi; Vandermeulen, Jack H; Sali, Arpana; Jahnke, Vanessa; Duguez, Stephanie; DuBois, Debra; Rose, Mary C; Nagaraju, Kanneboyina; Hoffman, Eric P.

In: The Journal of Pharmacology and Experimental Therapeutics, Vol. 343, No. 1, 10.10.2012, p. 225-232.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects

AU - Baudy, Andreas R

AU - Reeves, Erica K M

AU - Damsker, Jesse M

AU - Heier, Christopher

AU - Garvin, Lindsay M

AU - Dillingham, Blythe C

AU - McCall, John

AU - Rayavarapu, Sree

AU - Wang, Zuyi

AU - Vandermeulen, Jack H

AU - Sali, Arpana

AU - Jahnke, Vanessa

AU - Duguez, Stephanie

AU - DuBois, Debra

AU - Rose, Mary C

AU - Nagaraju, Kanneboyina

AU - Hoffman, Eric P

PY - 2012/10/10

Y1 - 2012/10/10

N2 - Glucocorticoids are standard of care for many inflammatory conditions, but chronic use is associated with a broad array of side effects. This has led to a search for dissociative glucocorticoids--drugs able to retain or improve efficacy associated with transrepression [nuclear factor-κB (NF-κB) inhibition] but with the loss of side effects associated with transactivation (receptor-mediated transcriptional activation through glucocorticoid response element gene promoter elements). We investigated a glucocorticoid derivative with a Δ-9,11 modification as a dissociative steroid. The Δ-9,11 analog showed potent inhibition of tumor necrosis factor-α-induced NF-κB signaling in cell reporter assays, and this transrepression activity was blocked by 17β-hydroxy-11β-[4-dimethylamino phenyl]-17α-[1-propynyl]estra-4,9-dien-3-one (RU-486), showing the requirement for the glucocorticoid receptor (GR). The Δ-9,11 analog induced the nuclear translocation of GR but showed the loss of transactivation as assayed by GR-luciferase constructs as well as mRNA profiles of treated cells. The Δ-9,11 analog was tested for efficacy and side effects in two mouse models of muscular dystrophy: mdx (dystrophin deficiency), and SJL (dysferlin deficiency). Daily oral delivery of the Δ-9,11 analog showed a reduction of muscle inflammation and improvements in multiple muscle function assays yet no reductions in body weight or spleen size, suggesting the loss of key side effects. Our data demonstrate that a Δ-9,11 analog dissociates the GR-mediated transcriptional activities from anti-inflammatory activities. Accordingly, Δ-9,11 analogs may hold promise as a source of safer therapeutic agents for chronic inflammatory disorders.

AB - Glucocorticoids are standard of care for many inflammatory conditions, but chronic use is associated with a broad array of side effects. This has led to a search for dissociative glucocorticoids--drugs able to retain or improve efficacy associated with transrepression [nuclear factor-κB (NF-κB) inhibition] but with the loss of side effects associated with transactivation (receptor-mediated transcriptional activation through glucocorticoid response element gene promoter elements). We investigated a glucocorticoid derivative with a Δ-9,11 modification as a dissociative steroid. The Δ-9,11 analog showed potent inhibition of tumor necrosis factor-α-induced NF-κB signaling in cell reporter assays, and this transrepression activity was blocked by 17β-hydroxy-11β-[4-dimethylamino phenyl]-17α-[1-propynyl]estra-4,9-dien-3-one (RU-486), showing the requirement for the glucocorticoid receptor (GR). The Δ-9,11 analog induced the nuclear translocation of GR but showed the loss of transactivation as assayed by GR-luciferase constructs as well as mRNA profiles of treated cells. The Δ-9,11 analog was tested for efficacy and side effects in two mouse models of muscular dystrophy: mdx (dystrophin deficiency), and SJL (dysferlin deficiency). Daily oral delivery of the Δ-9,11 analog showed a reduction of muscle inflammation and improvements in multiple muscle function assays yet no reductions in body weight or spleen size, suggesting the loss of key side effects. Our data demonstrate that a Δ-9,11 analog dissociates the GR-mediated transcriptional activities from anti-inflammatory activities. Accordingly, Δ-9,11 analogs may hold promise as a source of safer therapeutic agents for chronic inflammatory disorders.

KW - glucocorticoids

U2 - 10.1124/jpet.112.194340

DO - 10.1124/jpet.112.194340

M3 - Article

VL - 343

SP - 225

EP - 232

JO - Journal of Pharmacology and Experimental Therapeutics

T2 - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -